The Statute Nobody Outside Regulatory Affairs Reads
Most coverage of America's 1,000-plus active drug shortages focuses on the symptom: empty shelves for amiodarone, cisplatin or amoxicillin suspension. Fewer people examine the mechanism that is supposed to give FDA advance warning before that happens. That mechanism is Section 506C of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 356c, and it is a genuinely narrow, legally specific reporting duty, not a general transparency gesture.
506C applies to manufacturers of drugs that are life-supporting, life-sustaining, or intended for use in the prevention or treatment of a debilitating disease or condition, including most sterile injectables, oncology drugs, anesthetics and certain biologics. If a covered manufacturer is the sole source, or one of a small number of sources, of such a product, it must notify FDA's Center for Drug Evaluation and Research at least six months before a discontinuance or an interruption in manufacturing that could reasonably be expected to lead to a shortage. Where six months' notice is not possible, the statute requires notification as soon as practicable, and no later than five business days after the manufacturer knows the interruption will occur.
What Actually Has to Be Disclosed
The content requirement is specific. A 506C notification must identify the drug by name and NDC, state the reason for the interruption or discontinuance (a plant shutdown, an API supply failure, a CGMP remediation, a business decision to exit a product line), and specify the expected duration if known. FDA does not require public disclosure of proprietary manufacturing details, capacity figures or contract terms, which is why the published shortage database on FDA's website often shows a generic 'demand increase' or 'manufacturing delay' rather than the underlying commercial reason.
Congress has widened this obligation twice in the past decade. The 2012 FDA Safety and Innovation Act (FDASIA) created the six-month advance-notice standard and gave FDA's Drug Shortage Staff formal statutory footing. The 2020 CARES Act, passed in the early months of the COVID-19 pandemic, extended 506C to cover interruptions in the supply of active pharmaceutical ingredients and other critical components, not just finished-dose manufacturing, and required manufacturers to develop and maintain risk management plans for their own supply chains. The 2022 Food and Drug Omnibus Reform Act (FDORA) went further still, mandating that manufacturers of drugs FDA designates as 'essential' report annual production volumes by NDC and maintain formal redundancy plans, with enforcement provisions phased in through 2023 and 2024.
Why Noncompliance Is a Public Problem, Not a Private One
FDA's enforcement tool for 506C failures is unusual. Rather than a warning letter or an untitled letter, the statute directs FDA to issue a formal notification of noncompliance to the manufacturer, and, since 2015, FDA has published the identities of companies that received one. That naming mechanism matters commercially. A hospital GPO or a 340B covered entity reviewing supplier reliability treats a public noncompliance notice as a credit-rating-style flag, feeding directly into sourcing decisions, backup-supplier negotiations and, increasingly, into resilience clauses that hospital systems and the Department of Defense have started writing into procurement contracts.
The Akorn Inc. collapse is the clearest recent illustration. When Akorn filed for its second bankruptcy and shut down abruptly in February 2023, several of its sterile injectable and ophthalmic lines went dark with little of the structured, phased notice 506C envisions, because a sudden liquidation does not fit neatly into a six-month planning window. FDA subsequently used the shortage list, rather than the noncompliance mechanism, as the operative tool, adding multiple Akorn NDCs to the active shortage database and using that listing to unlock downstream flexibilities for competitors and compounders.
The Commercial Leverage Hidden Inside a Shortage Listing
This is the part manufacturers understand better than most outside observers: a 506C notification and the resulting FDA shortage-list entry are not just disclosure, they are a regulatory switch that turns on a separate set of legal permissions. Once a drug is formally listed, FDA can exercise enforcement discretion allowing 503A and 503B compounding pharmacies to prepare copies of the shortage drug that would otherwise be prohibited under the Drug Quality and Security Act. FDA can also grant temporary importation authorizations for foreign-approved versions of the same molecule, as it did with insulin products and with certain cisplatin and carboplatin lots imported from Chinese manufacturer Qilu Pharmaceutical during the 2023 oncology-drug shortage. FDA can extend expiration dating on existing lots based on stability data, effectively creating supply out of inventory that would otherwise be discarded.
Each of these levers reshapes competitive dynamics. A shortage listing for a branded or sole-source generic can hand meaningful, if temporary, market share to a second manufacturer that ramps output, or to a 503B outsourcing facility that steps in as a compounded alternative. Conversely, the manufacturer that filed the 506C notice loses negotiating leverage with hospital systems for the duration of the listing, since group purchasing organizations begin diversifying contracts specifically to avoid single-source exposure the next time a plant issue recurs.
The Gap Regulators Still Cannot Close
The structural limitation of 506C is that it depends on manufacturers accurately predicting and voluntarily reporting their own disruptions, and the statute's scope excludes many generic sterile injectables from mandatory reporting if FDA determines multiple manufacturers exist, even when three of those four listed manufacturers have been non-operational for months. That definitional gap, more than any enforcement failure, explains why FDA's own shortage list understates the real fragility of categories like injectable anesthetics and electrolyte solutions, where nominal manufacturer counts look adequate on paper while actual, active production sits with one or two firms.
FDORA's essential medicines reporting requirement, now working through its implementation phase, is the first serious legislative attempt to close that gap by forcing volume disclosure rather than relying on discontinuance notices alone. Whether FDA uses that data to require redundant sourcing, rather than simply publishing more granular shortage statistics, will determine whether the next decade of 506C reform changes outcomes for hospital pharmacies or just improves the paperwork trail after the next plant goes dark.